Urothelial cancer biomarkers for detection and surveillance

被引:50
作者
Liou, LS
机构
[1] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA
[2] Abbott Labs, Abbott Mol, Abbott Pk, IL 60064 USA
关键词
D O I
10.1016/j.urology.2006.01.034
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cancer is a complex process, and the US cancer-specific death rate has not changed in the last 50 years. Cure of the disease usually results from early diagnosis and treatment. Urothelial carcinoma (UC) has the highest recurrence rate of any cancer and is the second most common cancer of the genitourinary tract. It usually does not present at a metastatic stage, but only 50% of patients treated with cystectomy survive >= 5 years. There is a UC surveillance protocol, which includes cystoscopy, imaging, and cytology, to detect progression and allow early treatment of life-threatening UC. Many patients may not complete the surveillance protocol, and the cost of these studies is increasing. In addition, questions about the efficacy of these modalities have been raised. Therefore, bladder urinary tumor markers have been developed to aid in the diagnosis and surveillance of UC. Because urothelial cells are bathed in the urine and are continually shed, UC presents a unique opportunity to monitor bladder neoplasia in a noninvasive fashion. Currently, there are many research bladder tumor markers, but only a few are commercially available US Food and Drug Administration (FDA)-approved products. The commercially available bladder tumor markers and potential future markers are discussed. The ideal urinary bladder tumor test is still unavailable, but the eventual "gold standard" will consist of multiplex assays that analyze nucleic acids and proteins for detection. In addition, these tests would also reveal to the clinician both prognostic information and therapeutic targets for personalized medical treatment.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 50 条
[1]  
American Cancer Society, 2005, CANC FACTS FIG 2005, P4
[2]  
ANDRIOLE G, 2004, UROLOGY TIMES 0701
[3]  
[Anonymous], UROL NURS
[4]  
[Anonymous], UROL NURS
[5]  
[Anonymous], 2002, CAMPBELLS UROLOGY
[6]  
*BARD DIAGN SCI IN, 1997, DAT FIL
[7]   Comparison of urine cell characteristics by flow cytometry and cytology in patients suspected of having bladder cancer [J].
Barlandas-Rendón, E ;
Müller, MM ;
García-Latorre, E ;
Heinschink, A .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (08) :817-823
[8]   The health economics of bladder cancer - A comprehensive review of the published literature [J].
Botteman, MF ;
Pashos, CL ;
Redaelli, A ;
Laskin, B ;
Hauser, R .
PHARMACOECONOMICS, 2003, 21 (18) :1315-1330
[9]  
Burchardt M, 2000, CLIN CHEM, V46, P595
[10]   Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage [J].
Chang, SS ;
Hassan, JM ;
Cookson, MS ;
Wells, N ;
Smith, JA .
JOURNAL OF UROLOGY, 2003, 170 (04) :1085-1087